Similarly, Wei and coworkers demonstrated a synergistic anticancer activity of phosphoglycerate dehydrogenase (PHGDH) blocking in combination with sorafenib treatment, leading to reduced α-ketoglutarate, serine, and NADPH levels in the presence of increased ROS production [64], suggesting the alteration of the oxidative potential of cancer cells as a further mechanism through which miR-494 inhibition might favor sorafenib sensitivity in HCC. This evidence concerns the gene PHGDH and cancer.